Related references
Note: Only part of the references are listed.The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives
A. D. Burden et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
Kenneth Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
The Impact of Methodological Approaches for Presenting Long-Term Clinical Data on Estimates of Efficacy in Psoriasis Illustrated by Three-Year Treatment Data on Infliximab
M. Papoutsaki et al.
DERMATOLOGY (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009
C. H. Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
European S3-Guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
The risk of mortality in patients with psoriasis - Results from a population-based study
Joel M. Gelfand et al.
ARCHIVES OF DERMATOLOGY (2007)
Efficacy and safety of etanercept in psoriasis/psoriatic arthritis - An updated review
Alberto Romero-Mate et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2007)
Risk of myocardial infarction in patients with psoriasis
Joel M. Gelfand et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Share Paper
